[go: up one dir, main page]

NO20082610L - Trihydrokloridformer av et dihydropteridonderivat og metoder for fremstilling - Google Patents

Trihydrokloridformer av et dihydropteridonderivat og metoder for fremstilling

Info

Publication number
NO20082610L
NO20082610L NO20082610A NO20082610A NO20082610L NO 20082610 L NO20082610 L NO 20082610L NO 20082610 A NO20082610 A NO 20082610A NO 20082610 A NO20082610 A NO 20082610A NO 20082610 L NO20082610 L NO 20082610L
Authority
NO
Norway
Prior art keywords
preparation
derivative
dihydropteridone
methods
trihydrochloride
Prior art date
Application number
NO20082610A
Other languages
English (en)
Norwegian (no)
Inventor
Guenter Linz
Rolf Schmid
Matthias Grauert
Peter Sieger
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of NO20082610L publication Critical patent/NO20082610L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Hydrogenated Pyridines (AREA)
NO20082610A 2006-02-08 2008-06-04 Trihydrokloridformer av et dihydropteridonderivat og metoder for fremstilling NO20082610L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06101414 2006-02-08
PCT/EP2007/051139 WO2007090844A1 (en) 2006-02-08 2007-02-07 Trihydrochloride forms of a dihydropteridinone derivative and processes for preparation

Publications (1)

Publication Number Publication Date
NO20082610L true NO20082610L (no) 2008-08-26

Family

ID=38008126

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082610A NO20082610L (no) 2006-02-08 2008-06-04 Trihydrokloridformer av et dihydropteridonderivat og metoder for fremstilling

Country Status (21)

Country Link
US (3) US7439358B2 (es)
EP (2) EP1984367A1 (es)
JP (1) JP5134552B2 (es)
KR (2) KR101462879B1 (es)
CN (2) CN102093360B (es)
AR (1) AR059349A1 (es)
AU (1) AU2007213752B2 (es)
BR (1) BRPI0707604A8 (es)
CA (1) CA2635834C (es)
EA (2) EA018663B1 (es)
EC (1) ECSP088589A (es)
IL (2) IL193217A (es)
NO (1) NO20082610L (es)
NZ (2) NZ570987A (es)
PE (2) PE20110100A1 (es)
SG (2) SG10201404755SA (es)
TW (1) TW200738716A (es)
UA (2) UA101060C2 (es)
UY (1) UY30136A1 (es)
WO (1) WO2007090844A1 (es)
ZA (1) ZA200804587B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3008074B2 (ja) 1995-05-24 2000-02-14 株式会社トキメック ジャイロ装置及びその製造方法
US6861422B2 (en) * 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
DE102004029784A1 (de) * 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004033670A1 (de) 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
US20060035903A1 (en) * 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US20060074088A1 (en) * 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US7728134B2 (en) * 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US7759485B2 (en) * 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
EP1632493A1 (de) * 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1630163A1 (de) * 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE102004058337A1 (de) * 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
US7439358B2 (en) * 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
TW200808325A (en) 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds
US7799781B2 (en) 2007-02-01 2010-09-21 Astrazeneca Ab 5,6,7,8-tetrahydropteridine derivatives as HSP90 inhibitors
WO2009019205A1 (en) * 2007-08-03 2009-02-12 Boehringer Ingelheim International Gmbh Crystalline form of a dihydropteridione derivative
JP5410432B2 (ja) 2007-09-28 2014-02-05 サイクラセル リミテッド プロテインキナーゼ阻害剤としてのピリミジン誘導体
EP2215091B1 (en) 2007-12-04 2016-03-30 Nerviano Medical Sciences S.r.l. Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors
EP2112152A1 (en) 2008-04-22 2009-10-28 GPC Biotech AG Dihydropteridinones as Plk Inhibitors
EP2325185A1 (en) 2009-10-28 2011-05-25 GPC Biotech AG Plk inhibitor
US8445503B2 (en) * 2009-12-23 2013-05-21 Elan Pharmaceuticals, Inc. Inhibitors of polo-like kinase
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
US20130131069A1 (en) 2011-05-13 2013-05-23 Boehringer Ingelheim International Gmbh Method for treatment of solid malignancies including advanced or metastatic solid malignancies
US9370535B2 (en) * 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
US20140154304A1 (en) 2012-11-30 2014-06-05 Boehringer Ingelheim International Gmbh Combination therapy with volasertib
WO2015011236A1 (en) 2013-07-26 2015-01-29 Boehringer Ingelheim International Gmbh Treatment of myelodysplastic syndrome
KR20160037233A (ko) * 2013-07-26 2016-04-05 베링거 인겔하임 인터내셔날 게엠베하 급성 골수성 백혈병 및 골수형성이상 증후군의 치료를 위한 데시타빈과 병용된 볼라세르티브
CN104003989B (zh) * 2014-05-26 2015-11-11 苏州明锐医药科技有限公司 伏拉塞替及其中间体的制备方法
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
CN105646398B (zh) * 2014-12-05 2018-09-07 上海医药工业研究院 N-((1r,4r)-4-(4-(环丙基甲基)哌嗪-1-基)环己基)乙酰胺的制备方法
WO2016206619A1 (zh) * 2015-06-26 2016-12-29 苏州晶云药物科技有限公司 Volasertib及其三盐酸盐的新晶型
WO2019145410A1 (en) 2018-01-25 2019-08-01 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia
IL316085A (en) 2022-04-08 2024-12-01 Inhibrx Biosciences Inc Dr5 agonist and plk1 inhibitor or cdk inhibitor combination therapy

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8303657A (nl) 1983-10-24 1985-05-17 Pharmachemie Bv Voor injectie geschikte, stabiele, waterige, zoutzuur bevattende oplossing van cisplatine, alsmede werkwijze ter bereiding daarvan.
DE3537761A1 (de) * 1985-10-24 1987-04-30 Bayer Ag Infusionsloesungen der 1-cyclopropyl-6-fluor-1,4-dihydro-4-oxo-7- (1-piperazinyl)-chinolin-3-carbonsaeure
JPH0276860A (ja) 1987-10-05 1990-03-16 Toyo Jozo Co Ltd ６−置換アルコキシ−２−オキソ−１，２−ジヒドロキノキサリン誘導体
EP0347146B1 (en) 1988-06-16 1993-09-01 Smith Kline & French Laboratories Limited Fused pyrimidine derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them
FR2645152B1 (fr) 1989-03-30 1991-05-31 Lipha 3h-pteridinones-4, procedes de preparation et medicaments les contenant
US5043270A (en) * 1989-03-31 1991-08-27 The Board Of Trustees Of The Leland Stanford Junior University Intronic overexpression vectors
CA2029651C (en) 1989-11-17 2000-06-06 David D. Davey Tricyclic pteridinones and a process for their preparation
US5198547A (en) * 1992-03-16 1993-03-30 South Alabama Medical Science Foundation, Usa Process for N5-formylating tetrahydropteridines
TW274550B (es) * 1992-09-26 1996-04-21 Hoechst Ag
EP1195372A1 (en) * 1994-04-18 2002-04-10 Mitsubishi Pharma Corporation N-heterocyclic substituted benzamide derivatives with antihypertensive activity
GB9418499D0 (en) * 1994-09-14 1994-11-02 Ciba Geigy Ag Process for producing n-methylated organic pigments
CO4410190A1 (es) 1994-09-19 1997-01-09 Lilly Co Eli 3-[4-(2-AMINOETOXI)-BENZOIL]-2-ARIL-6-HIDROXIBENZO [b] TIOFENO CRISTALINO
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
EP0825979B1 (en) 1995-05-19 2001-01-03 Novartis AG Process for the catalytic hydrogenation of aromatic nitro compounds
US5698556A (en) * 1995-06-07 1997-12-16 Chan; Carcy L. Methotrexate analogs and methods of using same
JP3887836B2 (ja) * 1995-12-21 2007-02-28 東ソー株式会社 Ｎ−メチルイミダゾール類の製造法
NZ334346A (en) 1996-09-23 2000-05-26 Lilly Co Eli Olanzapine dihydrate D comprising 2-methyl-4-(4-methyl-1-piperazinyl)-1OH-thieno[2,3-b][1,5]benzodiazepine and a formulation for use in treating central nervous system disorders
HUP0103466A3 (en) * 1998-08-11 2002-11-28 Pfizer Prod Inc Substituted 1,8-naphthyridin-4(1h)-ones having phosphodiesterase 4 inhibiting activity and pharmaceutical compositions thereof
EA005287B1 (ru) 1999-09-15 2004-12-30 Уорнер-Ламберт Компани Птеридиноны в качестве ингибиторов киназ
GB2359551A (en) 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
NZ520962A (en) 2000-03-06 2003-09-26 Warner Lambert Co 5-alkylpyrido[2,3-d]pyrimidines cyclin-dependent tyrosine kinase inhibitors
DE10018783A1 (de) 2000-04-15 2001-10-25 Fresenius Kabi De Gmbh Lagerstabile Infusionslösung des Ciprofloxacins mit verringertem Säuregehalt
US20020183292A1 (en) * 2000-10-31 2002-12-05 Michel Pairet Pharmaceutical compositions based on anticholinergics and corticosteroids
DE10058119A1 (de) * 2000-11-22 2002-05-23 Bayer Ag Pepinotan-Kit
US6756374B2 (en) 2001-01-22 2004-06-29 Hoffmann-La Roche Inc. Diaminothiazoles having antiproliferative activity
US6960589B2 (en) * 2001-03-09 2005-11-01 Abbott Laboratories Benzimidazoles that are useful in treating sexual dysfunction
WO2002076954A1 (en) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
WO2002076985A1 (en) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
US20030055026A1 (en) * 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US6806272B2 (en) * 2001-09-04 2004-10-19 Boehringer Ingelheim Pharma Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
UY27427A1 (es) 2001-09-04 2003-03-31 Boehringer Ingelheim Pharma Nuevas dihidro-pteridinonas, procedimientos para su preparación y su utilización como medicamentos
DE60130813T2 (de) * 2001-12-14 2008-07-03 Laboratoires Serono S.A., Coinsins Verfahren zum herbeiführen eines eisprungs mittels eines nicht-polypeptid camp-level-modulators
EP1501794A1 (de) * 2002-05-03 2005-02-02 Schering Aktiengesellschaft Thiazolidinone und ihre verwendung als polo like kinase inhibitoren
FR2843114B1 (fr) 2002-08-01 2004-09-10 Poudres & Explosifs Ste Nale Procede de monomethylation d'heterocycles azotes
JP2006505522A (ja) 2002-08-08 2006-02-16 スミスクライン ビーチャム コーポレーション チオフェン化合物
US20040127504A1 (en) * 2002-09-06 2004-07-01 Cowart Marlon D. Benzimidazoles that are useful in treating sexual dysfunction
GB2398565A (en) * 2003-02-18 2004-08-25 Cipla Ltd Imatinib preparation and salts
US6861422B2 (en) * 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
MXPA05009068A (es) 2003-02-26 2005-10-19 Boehringer Ingelheim Pharma Dihidro-pteridinonas, metodo para la produccion y uso del mismo en la forma de farmacos.
PL1605971T3 (pl) 2003-03-26 2010-10-29 Wyeth Llc Kompozycja immunogenna i sposoby
AU2004231342A1 (en) 2003-04-14 2004-11-04 Vectura Ltd Dry power inhaler devices and dry power formulations for enhancing dosing efficiency
CA2552540A1 (en) * 2004-01-17 2005-07-28 Boehringer Ingelheim International Gmbh Use of substituted pteridines for the treatment of diseases of the respiratory tract
DE102004002557A1 (de) * 2004-01-17 2005-08-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von substituierten Pyrimido(5,4-d)pyrimidinen zur Behandlung von Atemwegserkrankungen
DE102004029784A1 (de) * 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004033670A1 (de) 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
DE102004034623A1 (de) * 2004-07-16 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 6-Formyl-tetrahydropteridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US20060074088A1 (en) * 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US7759485B2 (en) 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US7728134B2 (en) * 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
EP1632493A1 (de) * 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1630163A1 (de) * 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
WO2006021547A1 (de) 2004-08-26 2006-03-02 Boehringer Ingelheim International Gmbh Pteridinone als plk (polo like kinase) inhibitoren
WO2006021548A1 (de) * 2004-08-27 2006-03-02 Boehringer Ingelheim International Gmbh Dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel
DE102004058337A1 (de) * 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
EP1915155A1 (en) 2005-08-03 2008-04-30 Boehringer Ingelheim International GmbH Dihydropteridinones in the treatment of respiratory diseases
EP2340837B1 (en) 2005-11-11 2017-03-15 Boehringer Ingelheim International GmbH Combination treatment of cancer comprising egfr/her2 inhibitors
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
CN101437795A (zh) * 2006-03-07 2009-05-20 阿斯利康(瑞典)有限公司 哌啶衍生物，制备它们的方法，它们作为治疗剂的用途和含有它们的药物组合物
CA2873524C (en) 2006-05-04 2018-02-20 Boehringer Ingelheim International Gmbh A polymeric form of 1-((4-methyl-quinazolin-2-yl)methyl)-3-7-(2-butyn-1-yl)-8-(3-(r)-aminopiperidin-1-yl)xanthine
WO2009019205A1 (en) 2007-08-03 2009-02-12 Boehringer Ingelheim International Gmbh Crystalline form of a dihydropteridione derivative
JP4642085B2 (ja) 2008-01-17 2011-03-02 日本下水道事業団 予測健全度を利用した施設管理および更新計画システム
EP2100894A1 (en) 2008-03-12 2009-09-16 4Sc Ag Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
EP2509592A1 (en) 2009-12-07 2012-10-17 Boehringer Ingelheim International GmbH Bibw 2992 for use in the treatment of triple negative breast cancer
WO2011101369A1 (en) 2010-02-17 2011-08-25 Boehringer Ingelheim International Gmbh Dihydropteridinones, method for production and use thereof
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
US20130131069A1 (en) 2011-05-13 2013-05-23 Boehringer Ingelheim International Gmbh Method for treatment of solid malignancies including advanced or metastatic solid malignancies
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors

Also Published As

Publication number Publication date
PE20071248A1 (es) 2008-01-15
ZA200804587B (en) 2009-04-29
NZ570987A (en) 2011-09-30
NZ606264A (en) 2014-08-29
BRPI0707604A2 (pt) 2011-05-10
EP2543669A3 (en) 2013-05-15
UA101060C2 (ru) 2013-02-25
EP2543669A2 (en) 2013-01-09
EA200801769A1 (ru) 2009-02-27
SG169397A1 (en) 2011-03-30
EA015389B1 (ru) 2011-08-30
UY30136A1 (es) 2007-09-28
US20120214995A1 (en) 2012-08-23
CA2635834C (en) 2014-10-21
KR20080093068A (ko) 2008-10-17
UA95625C2 (ru) 2011-08-25
EA018663B1 (ru) 2013-09-30
US20090030004A1 (en) 2009-01-29
IL236736A0 (en) 2015-02-26
IL193217A (en) 2017-06-29
AU2007213752A1 (en) 2007-08-16
CN102093360B (zh) 2014-11-05
AU2007213752B2 (en) 2013-01-17
CN101379064A (zh) 2009-03-04
CN102093360A (zh) 2011-06-15
AR059349A1 (es) 2008-03-26
WO2007090844A8 (en) 2007-10-11
CN101379064B (zh) 2012-01-25
US8664222B2 (en) 2014-03-04
KR20140082837A (ko) 2014-07-02
KR101445114B1 (ko) 2014-09-29
TW200738716A (en) 2007-10-16
HK1127772A1 (en) 2009-10-09
JP5134552B2 (ja) 2013-01-30
IL193217A0 (en) 2009-02-11
JP2009526017A (ja) 2009-07-16
ECSP088589A (es) 2008-07-30
US8188086B2 (en) 2012-05-29
CA2635834A1 (en) 2007-08-16
EP1984367A1 (en) 2008-10-29
BRPI0707604A8 (pt) 2017-12-26
WO2007090844A1 (en) 2007-08-16
SG10201404755SA (en) 2014-10-30
US7439358B2 (en) 2008-10-21
US20070203146A1 (en) 2007-08-30
PE20110100A1 (es) 2011-02-18
EA201100638A1 (ru) 2011-10-31
HK1158628A1 (en) 2012-07-20
KR101462879B1 (ko) 2014-11-18

Similar Documents

Publication Publication Date Title
NO20082610L (no) Trihydrokloridformer av et dihydropteridonderivat og metoder for fremstilling
TW200714589A (en) Phenylacetamides suitable as protein kinase inhibitors
WO2008094992A3 (en) 2-aminopyridine derivatives useful as kinase inhibitors
NZ592897A (en) Crystals of laquinimod sodium, and process for the manufacture thereof
WO2006018222A8 (de) Hydrate und polymorphe des 4-[[(7r)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-4-6-oxo-2-piperidinyl]amino]-3-methoxy-n-(1-methyl-4-piperidinyl)-benzamid, verfahren zu deren herstellung und deren verwendung als arzneimittel
NO20083918L (no) Dihydridiazepiner anvendelige som inhibitorer av proteinkinaser
DK1598333T3 (da) Fremgangsmåde til fremstilling af (1S)-4,5-dimethoxy-1-(methylaminomethyl)-benzocyclobutan og syreadditionssalte heraf samt anvendelse til syntese af ivabradin og syreadditionssalte heraf med farmaceutisk acceptable syrer
MX2009011059A (es) Aminopirimidinas utiles como inhibidores de cinasas.
WO2009012375A3 (en) Squarate kinase inhibitors
WO2008080891A3 (en) Process for the synthesis of derivatives of 3-amino-tetrahydrofuran-3-carboxylic acid and use thereof as medicaments
MX2008015250A (es) Sales de acido clorhidrico de la 6-metoxi-8-[4-(1-(5-fluoro)-quino lin-8-il-piperidin-4-il)-piperazin-1-il]-quinolina.
EA200800502A1 (ru) Соединения 3-аминокарбазола, фармацевтическая композиция, содержащая указанные соединения, и способ их получения
WO2007146202A3 (en) Succinate salts of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline and crystalline forms thereof
WO2008089436A3 (en) Crystalline forms of histone deacetylase inhibitors
WO2006066044A3 (en) Processes for producing 4-aminoquinazolines
WO2008059518A3 (en) Process for preparing crystalline aripiprazole
TW200740798A (en) Substituted amides, process for their manufacture and use thereof as medicaments
NO20081151L (no) Derivater av 5-pyridinyl-1-azabicklo[3.2.1]oktan, fremgangsmate derav og anvendelse av de samme i terapi
ATE411299T1 (de) Chlorsubstituierte guanidine
TH105084B (th) เกลือจำเพาะ, รูปแบบแอนไฮดรัสและรูปแบบที่เป็นผลึกของอนุพันธ์ไดไฮโดรพ์เทอริไดโอน
TH102696A (th) ไฮเดรตและพอลิมอร์ฟใหม่ของ 4-[[(7r)-8-ไซโคลเพนทิล-7-เอธิล-5,6,7,8-เททระไฮโดร-5-เมธิล-6-ออกโซ-2-ปเตอริไดนิล]อะมิโน]-3-เมธอกซิ-n-(1-เมธิล-4-ไพเพอริไดนิล)-เบนซามีด, กระบวนการสำหรับการผลิตสารเหล่านี้ และการใช้สารเหล่านี้เป็นสารรักษาโรค
PH12012500953A1 (en) Process for preparing a polymorph of the choline salt of a pyrimidin-5-yl acetic acid derivative
TW200616991A (en) Process for the preparation of n-(3,5-dichloropyrid-4-yl)-4-difluoromethoxy-8-methane sulfonamido-dibenzo[b,d]furan-1-carboxamide

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application